CCA
ABBV icon

Column Capital Advisors’s AbbVie ABBV Stock Holding History

Column Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$258K Sell
1,733
-7
-0.4% -$1.03K 0.04% 121
2023
Q2 		$235K Sell
1,740
-12
-0.7% -$1.76K 0.03% 127
2023
Q1 		$279K Buy
1,752
+4
+0.2% +$612 0.04% 109
2022
Q4 		$282K Buy
1,748
+5
+0.3% +$767 0.05% 95
2022
Q3 		$234K Buy
1,743
+4
+0.2% +$574 0.05% 101
2022
Q2 		$266K Buy
1,739
+4
+0.2% +$611 0.05% 89
2022
Q1 		$281K Sell
1,735
-706
-29% -$103K 0.05% 105
2021
Q4 		$330K Buy
2,441
+684
+39% +$80.8K 0.06% 94
2021
Q3 		$190K Sell
1,757
-9
-0.5% -$1.03K 0.04% 127
2021
Q2 		$199K Buy
1,766
+420
+31% +$47.3K 0.04% 120
2021
Q1 		$146K Sell
1,346
-37
-3% -$3.96K 0.03% 142
2020
Q4 		$148K Sell
1,383
-159
-10% -$15.3K 0.04% 133
2020
Q3 		$135K Buy
1,542
+254
+20% +$23.9K 0.04% 128
2020
Q2 		$126K Hold
1,288
– – 0.04% 129
2020
Q1 		$98K Sell
1,288
-636
-33% -$54.2K 0.04% 125
2019
Q4 		$170K Buy
+1,924
New +$160K 0.09% 104

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Column Capital Advisors's ABBV Position: Q3 2023 in Review

Column Capital Advisors reduced its AbbVie (ABBV) stake by 0.4% in Q3 2023, selling an estimated $1.03K and leaving 1,733 shares worth $258K. The position accounts for 0.04% of the portfolio, ranked #121.

Column Capital Advisors first reported a position in ABBV in Q4 2019 and has held it in 16 quarters since. The position peaked at $330K in Q4 2021. 3,112 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

  • Column Capital Advisors held 1,733 shares of AbbVie worth $258K as of Q3 2023.
  • Column Capital Advisors sold 7 AbbVie shares in Q3 2023, an estimated $1.03K.
  • AbbVie made up 0.04% of Column Capital Advisors's portfolio in Q3 2023, its #121 holding.
  • Column Capital Advisors first reported a position in AbbVie in Q4 2019 and has held it in 16 quarters since.
  • Column Capital Advisors's AbbVie position peaked at $330K in Q4 2021.
  • 3,112 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.